The Capitello 281 study established PTEN deficiency not just as a biomarker, but as a distinct subpopulation of prostate cancer. This subtype has a poor prognosis, higher rates of symptomatic bone complications, and often progresses with a relatively low Prostate-Specific Antigen (PSA), making it biologically distinct from other prostate cancers.

The advent of highly sensitive PSMA PET imaging is changing the management of biochemically recurrent prostate cancer. Rather than relying on fixed PSA thresholds from older trials like EMBARK to restart therapy, clinicians now use PET imaging at lower PSA levels to guide decisions, aiming to extend treatment-free intervals.

The AKT pathway, activated by PTEN loss, drives cancer growth independently of the androgen receptor, which controls PSA production. This discordance means clinicians cannot rely on PSA alone and must use systematic imaging to detect progression in this specific patient subgroup.

Patients with high-risk genomic features like PTEN or TP53 loss may develop new or worsening metastatic disease visible on imaging without a rise in their PSA levels. This mandates routine cross-sectional imaging, as PSA alone is an unreliable marker for progression in this subgroup.

Intensive treatments like ADT plus an ARPI can suppress a patient's PSA so effectively that it becomes an unreliable marker of disease status. Patients may show radiographic progression on scans even while their PSA remains low and they feel clinically well. This discordance necessitates periodic imaging to avoid missing actual disease progression.

Data from the CAPItello trial showed a significant number of patients with PTEN deficiency experienced radiological progression without a corresponding PSA increase. This challenges the standard reliance on PSA for monitoring in high-risk prostate cancer and suggests a need for more frequent, personalized imaging protocols to detect progression earlier.

Landmark clinical trials (CONDOR, SPOTlight) demonstrate that PSMA PET imaging effectively identifies recurrent prostate cancer in a high percentage of patients even with very low PSA levels. This challenges the traditional paradigm of waiting for higher PSA thresholds before imaging, enabling earlier and more precise intervention.

In patients with PTEN loss, cancer growth is driven by the PI3K-AKT pathway, which doesn't activate the PSA gene. This can lead to significant disease progression with a low or stable PSA, making PSA a poor surrogate for disease activity in this sub-population.

Patients with PTEN-deficient prostate cancer often experience significant clinical or radiographic disease progression without a correspondingly rapid or high rise in PSA levels. This biological characteristic makes PSA an unreliable marker, necessitating a proactive strategy of frequent imaging to detect progression and intervene in a timely manner.